Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.

Synthakyne operates as a specialized 'cytokine engineering shop.' It develops its own assets in high-value areas like oncology (IL-2, IL-12) while simultaneously licensing its platform for other indications, such as inflammation, through major partnerships with Merck and Sanofi. This strategy generates capital and validates the core technology.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

For a small biotech, demonstrating that a drug is both clinically active on its own and well-tolerated is the most critical step. This de-risks the asset and opens the door to lucrative combination therapy partnerships with large pharma companies, as it minimizes the risk of combined toxicity killing the trial.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

Eupraxia views its delivery technology as a broad platform beyond one drug. It employs a dual strategy: advancing its own pipeline of proprietary drugs in-house while simultaneously seeking external partnerships for other applications, like cancer therapy. This hybrid model diversifies opportunities and aims to maximize the technology's value across multiple therapeutic areas.

Neurix's deals with Sanofi and Gilead involve the partner funding early development through human proof-of-concept, minimizing Neurix's upfront financial risk. Crucially, the deal structure allows Neurix to "opt-in" for a 50/50 profit share in the U.S. later, retaining significant upside on successful programs.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?

Shifting a drug's focus from treating an unpredictable illness (like severe influenza) to preventing a known side effect of a scheduled treatment (cancer immunotherapy) creates a much stronger, de-risked commercial case with a clear, prophylactic point of intervention.